ALSUntangled #61: melatonin

The ALSUntangled Group

Research output: Contribution to journalArticlepeer-review


ALSUntangled reviews alternative and off-label treatments for people with amyotrophic lateral sclerosis (ALS). Here we review melatonin. We show that it has plausible mechanisms, some positive (and some negative) pre-clinical studies, two cases in which cocktails of supplements including melatonin were associated with recovery of lost motor function, and a very small, flawed retrospective study suggesting that patients in the PRO-ACT database who reported taking melatonin progressed more slowly and lived longer compared to those who were not taking it. Melatonin appears safe, but an optimal dose and route of administration for ALS have not been determined. Based on all this, we support a pilot trial of melatonin in people with ALS but we cannot yet recommend it as a treatment.


  • Melatonin
  • alternative therapy
  • antioxidant
  • clinical trials
  • neuroinflammation
  • nutrition
  • survival

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'ALSUntangled #61: melatonin'. Together they form a unique fingerprint.

Cite this